RGNX · REGENXBIO Inc.
Market Cap
$637.69M
Shares
66.01M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$170.44M
+104.5%
FY2025
Net Income
-$193.88M
+14.6%
FY2025
Gross Margin
59.72%
+1pp
FY2024
Operating Margin
-94.58%
+185.4pp
FY2025
Diluted EPS
-$3.76
+18.1%
FY2025
Operating Cash Flow
-$123.96M
+28.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $174.48M | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M | $154.57M | $35.23M | $218.51M | $10.39M | $4.59M | $7.59M | $6.12M | $6.09M | |
| — | — | $33.57M | $37.21M | $54.55M | $51.83M | $35.71M | $8.24M | $9.64M | $1.71M | $98K | $98K | $122K | $173K | |
| — | — | $49.76M | $53.03M | $58.18M | $418.51M | $118.85M | $26.99M | $208.87M | $8.68M | $4.49M | $7.49M | $6M | $5.91M | |
| — | — | 59.72% | 58.76% | 51.61% | 88.98% | 76.89% | 76.61% | 95.59% | 83.56% | 97.86% | 98.71% | 98.01% | 97.16% | |
| $229.14M | $228.3M | $208.52M | $232.27M | $242.45M | $181.44M | $166.29M | $124.19M | $83.87M | $57.22M | $45.48M | $17.28M | $4.96M | $5.05M | |
| $85.56M | $82.86M | $76.62M | $88.49M | $85.28M | $79.33M | $63.82M | $51.82M | $36.85M | $27.23M | $23.59M | $11.91M | $3.85M | $5.47M | |
| $15.37M | $15.62M | $16.22M | $17.32M | $12.91M | $9.56M | $8.41M | $7.15M | $3.98M | $2.69M | $544K | $80K | $0 | $0 | |
| — | $0 | $0 | $3.7M | — | — | — | — | — | — | — | — | — | — | |
| $338.63M | $331.64M | $316.67M | $358.37M | $375.6M | $310.37M | $273.8M | $184.23M | $130.41M | $86.28M | $69.93M | $30.73M | $9.8M | $10.86M | |
| -$164.15M | -$161.2M | -$233.35M | -$268.13M | -$262.88M | $159.98M | -$119.23M | -$149M | $88.1M | -$75.89M | -$65.34M | -$23.14M | -$3.68M | -$4.78M | |
| — | -94.58% | -280.03% | -297.12% | -233.2% | 34.01% | -77.14% | -422.89% | 40.32% | -730.15% | -1423.84% | -304.92% | -60.16% | -78.46% | |
| -$148.78M | -$145.58M | -$217.13M | -$250.81M | -$249.97M | $169.54M | -$110.83M | -$141.85M | $92.08M | -$73.2M | -$64.8M | -$23.06M | -$3.68M | -$4.78M | |
| $41.95M | $45.01M | $12.66M | $6.86M | $23.25M | $26.28M | $771K | — | — | — | — | $20K | $321K | $611K | |
| $9.5M | $12.2M | $12.1M | $9.1M | $5.5M | — | — | — | — | — | — | — | — | — | |
| -$32.29M | -$32.68M | $6.24M | $4.48M | -$17.53M | -$18.73M | $13.22M | $51.51M | $16.02M | $2.72M | $1.94M | $326K | -$321K | -$611K | |
| — | — | — | — | -$79K | $5.19M | $4.92M | $37.77M | — | — | — | — | — | — | |
| — | -$193.88M | -$227.1M | -$263.65M | -$280.41M | $141.25M | -$106.01M | -$97.49M | $104.12M | -$73.17M | -$63.4M | -$22.81M | -$4M | — | |
| — | $0 | $0 | -$152K | -$84K | $13.41M | $5.24M | -$2.76M | $4.18M | $0 | -$435K | $0 | $0 | $0 | |
| -$196.43M | -$193.88M | -$227.1M | -$263.49M | -$280.32M | $127.84M | -$111.25M | -$94.73M | $99.94M | -$73.17M | -$62.97M | -$22.81M | -$4M | -$5.39M | |
| — | -113.75% | -272.54% | -291.99% | -248.68% | 27.18% | -71.98% | -268.88% | 45.74% | -704.02% | -1372.13% | -300.62% | -65.41% | -88.5% | |
| — | — | — | -$263.49M | -$280.32M | $127.84M | -$111.25M | -$94.73M | $99.94M | -$73.17M | -$62.97M | -$23.8M | -$4.82M | -$5.81M | |
| -$196.56M | -$193.82M | -$223.41M | -$252.52M | -$293.15M | $125.63M | -$111.82M | -$93.85M | $99.93M | -$73.85M | -$62.28M | -$23.53M | -$4M | -$5.39M | |
| USD/shares | -$3.79 | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $3.01 | -$2.98 | -$2.58 | $2.99 | -$2.45 | -$2.38 | — | — | — |
| USD/shares | -$3.79 | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $2.91 | -$2.98 | -$2.58 | $2.73 | -$2.45 | -$2.38 | — | — | — |
| shares | — | 51.57M | 49.51M | 43.73M | 43.15M | 42.44M | 37.28M | 36.69M | 33.43M | 29.88M | 26.41M | 9.17M | 2.64M | 2.32M |
| shares | — | 51.57M | 49.51M | 43.73M | 43.15M | 43.91M | 37.28M | 36.69M | 36.65M | 29.88M | 26.41M | 9.17M | 2.64M | 2.32M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.00×
EV/EBIT
—
Peer median 11.02×
P/E (TTM)
—
Peer median 12.82×
Peer medians compare against the 307 similar-size Biotechnology companies (of 508 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| License And Service | $156,267,000 | $81,960,000 | $90,242,000 | $112,724,000 | $470,347,000 | $154,567,000 | $35,233,000 | $218,505,000 |
| Zolgensma and Itvisma Royalties | $83,177,000 | $81,505,000 | — | — | — | — | — | — |
| Zolgensma Royalties | $82,536,000 | $81,505,000 | $85,319,000 | $101,919,000 | $94,978,000 | $61,631,000 | $20,829,000 | — |
| Nippon Shinyaku Licenses | $72,903,000 | — | — | — | — | — | — | — |
| Total Service Revenue | $14,174,000 | $1,368,000 | — | — | — | — | — | — |
| Service | $14,174,000 | $1,368,000 | — | — | — | — | — | — |
| Nippon Shinyaku Services | $11,822,000 | — | — | — | — | — | — | — |
| Other Service Revenue | $2,352,000 | $1,368,000 | — | — | — | — | — | — |
| Itvisma Royalties | $641,000 | — | — | — | — | — | — | — |
| AbbVie Collaboration and License Agreement | — | — | — | — | $370,000,000 | — | — | — |
| Achievement of Sales-Based Milestone for Zolgensma | — | — | — | — | — | $80,000,000 | — | — |
| License | — | — | — | — | — | $3,500,000 | $3,500,000 | $176,066,000 |
Key facts
CIK
1590877
CUSIP
75901B107
13F (30d)
148 filings
142 filers
Visit website
Investor relations